Biohaven Pharmaceutical CEO Vlad Coric appeared on CNBC Wednesday to discuss the company’s efforts to commercialize an oral solution to prevent migraine attacks.
After launching Nurtec ODT, an oral treatment for acute migraine attacks earlier this year, the biotech’s goal is to get the same therapy to work to stop symptoms before they set in.
Biohaven took a step closer to implementation last month when the US Food and Drug Administration accepted its request for review.
“I hope that in about six months we will be the first oral CGRP with the indication for the prevention of migraines,” he told Jim Cramer in a “Bad money“Interview.” Patients deserve to know that they can prevent their next episode and not wait for this migraine to occur. “
When the CGRP protein, or the peptide related to the calcitonin gene, is released in the brain, it creates pain associated with a migraine attack. Nurtec ODT was the first CGRP blocker in tablet form to be approved by the FDA earlier this year.
Biohaven anticipates that the treatment of acute migraines could be used as a prevention indicator in mid-2021. The FDA has given the company a period in the second quarter, known as the PDUFA date, to review drug usage. PDUFA is an acronym for the Prescription Drug User Fee Act, which was passed in 1992 to fund the new drug approval process.
The FDA previously approved several GGRP inhibitors for other drug manufacturers, although the drugs must be injected into the body.
“If we get approval for prevention, it will be the first and only oral CGRP to be indicated as double acting for acute and preventive therapy,” Coric said. “I hope that one day in the near future, patients can take something to prevent their migraines with an oral drug rather than an injectable drug.”
Migraines, which can cause debilitating headaches, is a poorly understood disease that is often undiagnosed. According to the Migraine Research Foundation, around 39 million people had the disease in 2019.
Coric told the company which teamed up with celebrity Khloe Kardashian To advertise the tablet, an “explosive growth” of the Nurtec recipes has been recorded since the market launch. Biohaven has reported that it has reached more than 220,000 recipes since launching over six months ago.
Biohaven’s shares rose nearly 2% on Wednesday to hit a record close of $ 98.24. The stock is up 80% since the start of the year.